Life Sciences — Total Capital Expenditures
Becton, Dickinson and Company Life Sciences — Total Capital Expenditures increased by 15.7% to $125.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.6%, from $114.00M to $125.00M. Over 2 years (FY 2023 to FY 2025), Life Sciences — Total Capital Expenditures shows a downward trend with a -6.7% CAGR.
Analysis
How to read this metric
An increase suggests investment in future capacity or efficiency, while a significant decrease may indicate reduced capital intensity or a shift toward asset-light strategies.
Detailed definition
This metric represents the total cash outflows for the acquisition, construction, or improvement of long-lived physical...
Peer comparison
Similar to 'Capital Expenditures' or 'Additions to Property, Plant, and Equipment' reported by peer medical technology and life sciences firms.
bdx_segment_life_sciences_total_capital_expendituresHistorical Data
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $243.00M | $74.25M | $452.00M | $74.25M | $183.00M | $53.25M | $222.00M | $53.25M | $253.00M | $53.25M | $315.00M | $53.25M | $208.00M | $181.00M | $191.00M | $294.00M | $116.00M | $134.00M | $179.00M | $296.00M | $105.00M | $114.00M | $189.00M | $352.00M | $108.00M | $125.00M |
| QoQ Change | — | -69.4% | +508.8% | -83.6% | +146.5% | -70.9% | +316.9% | -76.0% | +375.1% | -79.0% | +491.5% | -83.1% | +290.6% | -13.0% | +5.5% | +53.9% | -60.5% | +15.5% | +33.6% | +65.4% | -64.5% | +8.6% | +65.8% | +86.2% | -69.3% | +15.7% |
| YoY Change | — | — | — | — | — | — | — | — | +4.1% | -78.1% | -30.3% | -88.2% | +13.7% | -18.5% | -24.5% | -6.7% | -44.2% | -26.0% | -6.3% | +0.7% | -9.5% | -14.9% | +5.6% | +18.9% | +2.9% | +9.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's life sciences — total capital expenditures?
- Becton, Dickinson and Company (BDX) reported life sciences — total capital expenditures of $125.00M in Q1 2026.
- How has Becton, Dickinson and Company's life sciences — total capital expenditures changed year-over-year?
- Becton, Dickinson and Company's life sciences — total capital expenditures increased by 9.6% year-over-year, from $114.00M to $125.00M.
- What is the long-term trend for Becton, Dickinson and Company's life sciences — total capital expenditures?
- Over 2 years (2023 to 2025), Becton, Dickinson and Company's life sciences — total capital expenditures has grown at a -6.7% compound annual growth rate (CAGR), from $874.00M to $760.00M.
- What does life sciences — total capital expenditures mean?
- The total amount of money spent by the Life Sciences segment on physical assets like machinery, facilities, and equipment.